{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:34:02Z","timestamp":1783510442543,"version":"3.55.0"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>More than half of patients with breast, lung, or prostate cancer who have bone metastases have evidence of skeletal-related events (SREs). Denosumab is a fully human monoclonal antibody that binds to and neutralizes receptor activator of nuclear factor kappa-B ligand (RANKL) on osteoblasts and their precursors. The United States Food and Drug Administration (FDA)-approved dose of denosumab is 120\u2009mg every 4\u2009weeks; however, other schedules have been used in practice for patient convenience. Evidence for the safety and efficacy of alternative dosing intervals is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient &amp; Methods:<\/jats:title>\n                    <jats:p>Adult patients with solid cancers and bone metastases who received at least two doses of denosumab 120\u2009mg were reviewed. Patients were grouped based on an average denosumab dosing interval of &lt;5\u2009weeks (short-interval) versus 5\u201311\u2009weeks (medium-interval) versus \u2a7e12\u2009weeks (long-interval). The primary outcome was the time to first SRE while on denosumab between the short- and medium-interval groups. The secondary outcomes were overall survival (OS), efficacy comparisons between the other groups, and safety events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There was no significant difference in median time to first SRE between the short- and medium-interval denosumab groups [33.2 versus 28.4\u2009months, hazard ratio (HR): 1.13, 95% confidence interval (CI): 0.66\u20131.92, p\u2009=\u20090.91] or the medium- and long-interval dosing groups (28.4 versus 32.2\u2009months, HR: 1.15, 95% CI: 0.66\u20132.01, p\u2009=\u20090.62). Median OS was not found to differ significantly between any of the groups. There were significantly more hospitalizations in the short-interval dosing group than the other groups (55.2% versus 33.8% versus 30.4%, p\u2009&lt;\u20090.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Extending denosumab dosing intervals does not appear to negatively impact time to first SRE and is associated with fewer hospitalizations in real-world patients with solid cancers and bone metastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1758835920982859","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T04:18:15Z","timestamp":1608697095000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5723-1721","authenticated-orcid":false,"given":"Aseala I.","family":"Abousaud","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Services, Emory Healthcare, 5665 Peachtree Dunwoody Road NE, Atlanta, GA 30342, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan S.","family":"Barbee","sequence":"additional","affiliation":[{"name":"Global Medical Information Specialist, Oncology at Med Communications Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Caulfield","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Rollins School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Boykin","sequence":"additional","affiliation":[{"name":"Medical Science Liason, Novocure Inc., Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley C.","family":"Carthon","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthi","family":"Gogineni","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"bibr1-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1887-3"},{"key":"bibr2-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"bibr3-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2016.62"},{"key":"bibr4-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4614"},{"key":"bibr5-1758835920982859","unstructured":"National Comprehensive Cancer Network. Breast cancer, version 6.2020. 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. (2020, accessed 14 December 2020)"},{"key":"bibr6-1758835920982859","unstructured":"National Comprehensive Cancer Network. Prostate cancer version 3.2020. 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. (2020, accessed 14 December 2020)"},{"key":"bibr7-1758835920982859","unstructured":"National Comprehensive Cancer Network. Non-small cell lung cancer, version 1.2021. 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. (2021, accessed 14 December 2020)"},{"key":"bibr8-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"bibr9-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"bibr10-1758835920982859","unstructured":"Denosumab (Xgeva). Prescribing information: Amgen Inc. Thousand Oaks, CA, 2018."},{"key":"bibr11-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv284"},{"key":"bibr12-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2146"},{"key":"bibr13-1758835920982859","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.117"},{"key":"bibr14-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8604"},{"key":"bibr15-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11501"},{"key":"bibr16-1758835920982859","volume-title":"Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks","author":"Berset C.","year":"2020"},{"key":"bibr17-1758835920982859","first-page":"28","volume-title":"Presented at the 9th International Conference on Cancer-Induced Bone Disease","author":"Miller R","year":"2009"},{"key":"bibr18-1758835920982859","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00076"},{"key":"bibr19-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058361"},{"key":"bibr20-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0046"},{"key":"bibr21-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060706"},{"key":"bibr22-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1038\/nature09495"},{"key":"bibr23-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23009"},{"key":"bibr24-1758835920982859","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20235841"},{"key":"bibr25-1758835920982859","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03051"},{"key":"bibr26-1758835920982859","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041239"},{"key":"bibr27-1758835920982859","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666190730113123"},{"key":"bibr28-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31826aec2b"},{"key":"bibr29-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2350-5"},{"key":"bibr30-1758835920982859","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0170"},{"key":"bibr31-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.5209"},{"key":"bibr32-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219842277"},{"key":"bibr33-1758835920982859","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051209"},{"key":"bibr34-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1111\/clr.12556"},{"key":"bibr35-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04988-7"},{"key":"bibr36-1758835920982859","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-016-0810-7"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1758835920982859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1758835920982859","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1758835920982859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:25:29Z","timestamp":1777587929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1758835920982859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":36,"alternative-id":["10.1177\/1758835920982859"],"URL":"https:\/\/doi.org\/10.1177\/1758835920982859","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"1758835920982859"}}